tradingkey.logo
tradingkey.logo
Suchen

ADMA Biologics Inc

ADMA
Zur Watchlist hinzufügen
8.610USD
+0.240+2.87%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
2.00BMarktkapitalisierung
12.38KGV TTM

mehr Informationen über ADMA Biologics Inc Unternehmen

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

ADMA Biologics Inc Informationen

BörsenkürzelADMA
Name des UnternehmensADMA Biologics Inc
IPO-datumOct 17, 2013
CEOGrossman (Adam S)
Anzahl der mitarbeiter677
WertpapierartOrdinary Share
GeschäftsjahresendeOct 17
Addresse465 State Route 17
StadtRAMSEY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl07446
Telefon12014785552
Websitehttps://www.admabiologics.com/
BörsenkürzelADMA
IPO-datumOct 17, 2013
CEOGrossman (Adam S)

Führungskräfte von ADMA Biologics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.94M
-33.49%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
602.30K
+5.21%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
175.82K
+10.98%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
-12.24%
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
-98.17%
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
2.03K
-12280.23%
Dr. Young T. Kwon, Ph.D.
Dr. Young T. Kwon, Ph.D.
Independent Director
Independent Director
--
--
Ms. Alison C. Finger
Ms. Alison C. Finger
Independent Director
Independent Director
--
--
Ms. Kaitlin Kestenberg
Ms. Kaitlin Kestenberg
Chief Operating Officer, Senior Vice President - Compliance
Chief Operating Officer, Senior Vice President - Compliance
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.94M
-33.49%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
602.30K
+5.21%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
175.82K
+10.98%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
-12.24%
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
-98.17%
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
2.03K
-12280.23%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von ADMA Biologics Inc?

Die fünf größten Anteilseigner von ADMA Biologics Inc sind: Mr. Adam S. Grossman

Wie viele Institutionen halten Anteile an ADMA Biologics Inc (ADMA)?

Mit Stand vom 2026Q1 halten 784 Institutionen Anteile an ADMA Biologics Inc, mit einem Gesamtmarktwert von etwa 218.01M, was 94.06% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -33855143.00 gestiegen.